The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Randomized, double‐blind, placebo‐controlled trial of the once‐daily GLP ‐1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea ( GetGoal ‐L‐Asia)
Open accessAbstract
Aims: To assess the efficacy and safety of once‐daily lixisenatide versus placebo in Asian patients with type 2 diabetes insufficiently controlled on basal insulin ± sulfonylurea. Methods: In this 24‐week, randomized, double‐blind, placebo‐controlled, parallel‐group, multicentre study, participants (mean baseline HbA 1c 8.53%) from Japan, Republic of Korea, Taiwan and the Philippines received lixisenatide (n = 154) or placebo (n = 157) in a stepwise dose increase to 20 µg once daily. The primary endpoint was HbA 1c change from baseline to week 24. Results: Once‐daily lixisenatide significantly improved HbA 1c versus placebo ( LS mean difference vs. placebo = −0.88% [95% CI = −1.116, −0.650]; p < 0.0001), and allowed more patients to achieve HbA 1c <7.0% (35.6 vs. 5.2%) and ≤6.5% (17.8 vs. 1.3%). Lixisenatide also significantly improved 2‐h postprandial plasma glucose and glucose excursion, average 7‐point self‐monitored blood glucose and fasting plasma glucose. Lixisenatide was well tolerated; 86% of patients on lixisenatide completed the study versus 92% on placebo. Ten (6.5%) lixisenatide and 9 (5.7%) placebo patients experienced serious adverse events. More lixisenatide patients [14 (9.1%)] discontinued for adverse events versus placebo [5 (3.2%)], mainly with gastrointestinal causes. Nausea and vomiting were reported in 39.6 and 18.2% of patients on lixisenatide versus 4.5 and 1.9% on placebo. Symptomatic hypoglycaemia was more frequent with lixisenatide (42.9%) versus placebo (23.6%), but was similar between groups (32.6 vs. 28.3%, respectively), in those not receiving sulfonylureas. No severe hypoglycaemia was reported. Conclusions: In an Asian type 2 diabetes population insufficiently controlled by basal insulin ± sulfonylurea, once‐daily lixisenatide significantly improved glycaemic control, with a pronounced postprandial effect, and was well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Rodbard, H. W., Jellinger, P. S., Davidson, J. A., Einhorn, D., Garber, A. J., Grunberger, G., Handelsman, Y., Horton, E. S., Lebovitz, H., Levy, P., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.6.540 · Cited by 942
GIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746
Self-citationBuse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506
Ceriello, A., & Colagiuri, S. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02565.x · Cited by 268
Riddle, M., Umpierrez, G., DiGenio, A., Zhou, R., & Rosenstock, J. (2011) · Diabetes Care · doi:10.2337/dc11-0632 · Cited by 219
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E., & on behalf of the EFC6018 GetGoal-Mono Study Investigators (2012) · Diabetes Care · doi:10.2337/dc11-1935 · Cited by 218
Self-citationWerner, U., Haschke, G., Herling, A. W., & Kramer, W. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.05.008 · Cited by 173
Ratner, R. E., Rosenstock, J., Boka, G., & on behalf of the DRI6012 Study Investigators (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03020.x · Cited by 157
Self-citationBolli, G. B., Munteanu, M., Dotsenko, S., Niemoeller, E., Boka, G., Wu, Y., & Hanefeld, M. (2014) · Diabetic Medicine · doi:10.1111/dme.12328 · Cited by 144
Self-citationMadsbad, S. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.008 · Cited by 134
Seino, Y., Rasmussen, M. F., Nishida, T., & Kaku, K. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003672551 · Cited by 123
Self-citationSeino, Y., Rasmussen, M. F., Zdravkovic, M., & Kaku, K. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.03.018 · Cited by 117
Self-citationYang, W., Chen, L., Ji, Q., Liu, X., Ma, J., Tandon, N., Bhattacharyya, A., Kumar, A., Kim, K.-W., Yoon, K., et al. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01323.x · Cited by 97
Kaku, K., Rasmussen, M. F., Clauson, P., & Seino, Y. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01194.x · Cited by 93
Self-citationYabe, D., Kuroe, A., Lee, S., Watanabe, K., Hyo, T., Hishizawa, M., Kurose, T., Deacon, C. F., Holst, J. J., Hirano, T., et al. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00010.x · Cited by 91
Self-citationGao, Y., Yoon, K., Chuang, L., Mohan, V., Ning, G., Shah, S., Jang, H. C., Wu, T.-J., Johns, D., Northrup, J., et al. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.09.037 · Cited by 91
Yabe, D., Watanabe, K., Sugawara, K., Kuwata, H., Kitamoto, Y., Sugizaki, K., Fujiwara, S., Hishizawa, M., Hyo, T., Kuwabara, K., et al. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00141.x · Cited by 64
Self-citationKadowaki, T., Namba, M., Imaoka, T., Yamamura, A., Goto, W., Boardman, M. K., & Sowa, H. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00084.x · Cited by 55
Kadowaki, T., Namba, M., Yamamura, A., Sowa, H., Wolka, A. M., & Brodows, R. G. (2009) · Endocrine Journal · doi:10.1507/endocrj.k08e-296 · Cited by 51
Kaku, K., Rasmussen, M. F., Nishida, T., & Seino, Y. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00128.x · Cited by 49
Self-citationThe safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes
Russell-Jones, D. L. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02465.x · Cited by 42
Seino, Y., Rasmussen, M. F., Nishida, T., & Kaku, K. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00103.x · Cited by 35
Self-citationInagaki, N., Ueki, K., Yamamura, A., Saitô, H., & Imaoka, T. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00137.x · Cited by 15
Cited by
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
“Lixisenatide has been also used in combination with basal insulin therapy [188-190] .”
BackgroundMethodFilippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Japanese clinical practice guideline for diabetes 2019
Araki, E., Goto, A., Kondo, T., Noda, M., Noto, H., Origasa, H., Osawa, H., Taguchi, A., Tanizawa, Y., Tobe, K., et al. (2020) · Diabetology International · doi:10.1007/s13340-020-00439-5 · Cited by 545
“• A decreased GFR and the occurrence of albuminuria are independent risk factors for cardiovascular disease [24].”
BackgroundInfluentialHtike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12849 · Cited by 416
Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.
Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P.-L., Wijayasinghe, N., & Norwood, P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00070 · Cited by 412
Metadata
- Authors
- Seino, Y., Min, K. W., Niemoeller, E., Takami, A., & on behalf of the EFC10887 GETGOAL‐L Asia Study Investigators
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2012-05-30
- Volume
- 14
- Issue
- 10
- Pages
- 910-917
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1584571461
- Cited by
- 255
- References
- 26
- FWCI
- 25.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.